Amphotericin B resistance leads to enhanced proteinase and phospholipase activity and reduced germ tube formation in Candida albicans

Fungal Biology

Volumn 114, Issue 2-3, 2010, Pages 189-197

  Kumar, Rohitashw ^a   Shukla, P K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Amphotericin B; Antifungal resistance; Candida albicans; Virulence factors

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ASPARTIC PROTEINASE; ERGOSTEROL; PHOSPHOLIPASE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ENZYME ACTIVITY; FUNGUS; VIRULENCE;

ANIMAL; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; KIDNEY; MALE; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOUSE; NUCLEOTIDE SEQUENCE; PATHOGENICITY; SEQUENCE ALIGNMENT; UPREGULATION;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPARTIC ACID PROTEASES; BASE SEQUENCE; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ERGOSTEROL; GENE EXPRESSION REGULATION, FUNGAL; KIDNEY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PHOSPHOLIPASES; SEQUENCE ALIGNMENT; UP-REGULATION; VIRULENCE FACTORS;

CANDIDA ALBICANS;

EID: 77949331142     PISSN: 18786146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.funbio.2009.12.003     Document Type: Article

References (30)

1. Abe S., Satoh T., Tokuda Y., Tansho S., and Yamaguchi H. A rapid colorimetric assay for determination of leukocyte-mediated inhibition of mycelial growth of Candida albicans. Microbiology and Immunology 38 (1994) 385-388
2. Anderson J.B. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nature Reviews Microbiology 3 (2005) 547-556
3. Arthington-Skaggs B.A., Jradi H., Desai T., and Morrison C.J. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. Journal of Clinical Microbiology 37 (1999) 3332-3337
4. Barker K.S., Crisp S., Wiederhold N., Lewis R.E., Bareither B., Eckstein J., Barbuch R., Bard M., and Rogers P.D. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy 54 (2004) 376-385
5. Brayman T.G., and Wilks J.W. Sensitive assay for antifungal activity of glucan synthase inhibitors that uses germ tube formation in Candida albicans as an end point. Antimicrobial Agents and Chemotherapy 47 (2003) 3305-3310
6. Cannon R.D., Fischer F.J., Niimi K., Niimi M., and Arisawa M. Drug pumping mechanisms in Candida albicans. Japanese Journal of Medical Mycology 39 (1998) 73-78
7. Collin B., Clancy C.J., and Nguyen M.H. Antifungal resistance in non-albicans Candida species. Drug Resistance Updates 2 (1999) 9-14
8. Costa C.R., Jesuíno R.S., de Aquino Lemos J., de Fátima Lisboa Fernandes O., Hasimoto e Souza L.K., Passos X.S., and do Rosário Rodrigues Silva M. Effects of antifungal agents in sap activity of Candida albicans isolates. Mycopathologia 169 2 (2009) 91-98
9. Crandall M., and Edwards Jr. J.E. Segregation of proteinase-negative mutants from heterozygous Candida albicans. Journal of General Microbiology 133 (1987) 2817-2824
10. Dick J.D., Merz W.G., and Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrobial Agents and Chemotherapy 18 (1980) 158-163
11. Duggineni S., Srivastava G., Kundu B., Kumar M., Chaturvedi A.K., and Shukla P.K. A novel dodecapeptide from a combinatorial synthetic library exhibits potent antifungal activity and synergy with standard antimycotic agents. International Journal of Antimicrobial Agents 29 (2007) 73-78
12. Fekete-Forga K., Gyure L., and Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 43 (2000) 273-279
13. Hamilton-Miller J.M. Polyene-resistance in yeasts: a consideration of physiological and biochemical mechanisms. Microbios 8 (1973) 209-213
14. Ishiguro J., Saitou A., Duran A., and Ribas J.C. cps1+, a Schizosaccharomyces pombe gene homolog of Saccharomyces cerevisiae FKS genes whose mutation confers hypersensitivity to cyclosporin A and papulacandin B. Journal of Bacteriology 179 (1997) 7653-7662
15. Kelly S.L., Lamb D.C., Kelly D.E., Manning N.J., Loeffler J., Hebart H., Schumacher U., and Einsele H. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta 5,6-desaturation. FEBS Letters 400 (1997) 80-82
16. Krcmery V., and Barnes A.J. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. Journal of Hospital Infection 50 (2002) 243-260
17. Liu T.T., Lee R.E., Barker K.S., et al. Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrobial Agents and Chemotherapy 49 (2005) 2226-2236
18. Martínez J.P., Gil M.L., López-Ribot J.L., and Chaffin W.L. Serologic response to cell wall mannoproteins and proteins of Candida albicans. Clinical Microbiology Reviews 11 (1998) 121-141
19. National Committee for Clinical Laboratory Standard, 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
20. Nett J., Lincoln L., Marchillo K., Massey R., Holoyda K., Hoff B., VanHandel M., and Andes D. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrobial Agents and Chemotherapy 51 (2007) 510-520
21. Odds F.C. Morphogenesis in Candida albicans. Critical Reviews in Microbiology 12 (1985) 45-93
22. Ostrosky-Zeichner L., Marr K.A., Rex J.H., and Cohen S.H. Amphotericin B: time for a new gold standard. Clinical Infectious Diseases 37 (2003) 415-425
23. Ribeiro M.A., and Paula C.R. Up-regulation of ERG11 gene among fluconazole-resistant Candida albicans generated in vitro: is there any clinical implication?. Diagnostic Microbiology and Infectious Diseases 57 (2007) 71-75
24. Samaranayake L.P., Raeside J.M., and MacFarlane T.W. Factors affecting the phospholipase activity of Candida species in vitro. Sabouraudia 22 (1984) 201-207
25. Sanglard D., Ischer F., Parkinson T., et al. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrobial Agents and Chemotherapy 47 (2003) 2404-2412
26. Sobel J.D., Faro S., Force R.W., Foxman B., Ledger W.J., Nyirjesy P.R., Reed B.D., and Summers P.R. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. American Journal of Obstetrics & Gynecology 178 (1998) 203-211
27. Sudbery P., Gow N., and Berman J. The distinct morphogenic states of Candida albicans. Trends in Microbiology 12 (2004) 317-324
28. Swenson C.E., Perkins W.R., Roberts P., Ahmad I., Stevens R., Stevens D.A., and Janoff A.S. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?. Antimicrobial Agents and Chemotherapy 42 (1998) 767-771
29. Viviani M.A., De Marie S., Graybill J.R., Yamaguchi H., Anaissie E., and Caillot D. New approaches to antifungal chemotherapy. Medical Mycology 36 (1998) 194-206
30. Wu T., Wright K., Hurst S.F., and Morrison C.J. Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrobial Agents and Chemotherapy 44 (2000) 1200-1208